ABBVIE INC (4AB.DE) Fundamental Analysis & Valuation

FRA:4AB • US00287Y1091

195.8 EUR
-0.4 (-0.2%)
Last: Mar 12, 2026, 05:14 PM

This 4AB.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

Overall 4AB gets a fundamental rating of 5 out of 10. We evaluated 4AB against 83 industry peers in the Biotechnology industry. While 4AB belongs to the best of the industry regarding profitability, there are concerns on its financial health. 4AB may be a bit undervalued, certainly considering the very reasonable score on growth


Dividend Valuation Growth Profitability Health

7

1. 4AB.DE Profitability Analysis

1.1 Basic Checks

  • 4AB had positive earnings in the past year.
  • 4AB had a positive operating cash flow in the past year.
  • 4AB had positive earnings in each of the past 5 years.
  • In the past 5 years 4AB always reported a positive cash flow from operatings.
4AB.DE Yearly Net Income VS EBIT VS OCF VS FCF4AB.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

1.2 Ratios

  • 4AB has a better Return On Assets (3.12%) than 73.49% of its industry peers.
  • 4AB has a Return On Invested Capital of 14.42%. This is amongst the best in the industry. 4AB outperforms 91.57% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for 4AB is in line with the industry average of 12.16%.
  • The last Return On Invested Capital (14.42%) for 4AB is above the 3 year average (12.12%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.12%
ROE N/A
ROIC 14.42%
ROA(3y)3.28%
ROA(5y)5.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)12.12%
ROIC(5y)11.88%
4AB.DE Yearly ROA, ROE, ROIC4AB.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 -100

1.3 Margins

  • 4AB has a better Profit Margin (6.84%) than 73.49% of its industry peers.
  • In the last couple of years the Profit Margin of 4AB has declined.
  • 4AB has a better Operating Margin (34.23%) than 87.95% of its industry peers.
  • 4AB's Operating Margin has improved in the last couple of years.
  • 4AB's Gross Margin of 71.62% is in line compared to the rest of the industry. 4AB outperforms 59.04% of its industry peers.
  • 4AB's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 34.23%
PM (TTM) 6.84%
GM 71.62%
OM growth 3Y-0.41%
OM growth 5Y2.75%
PM growth 3Y-30.39%
PM growth 5Y-7.2%
GM growth 3Y0.04%
GM growth 5Y1.44%
4AB.DE Yearly Profit, Operating, Gross Margins4AB.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

3

2. 4AB.DE Health Analysis

2.1 Basic Checks

  • 4AB has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, 4AB has about the same amount of shares outstanding.
  • 4AB has about the same amout of shares outstanding than it did 5 years ago.
  • 4AB has a worse debt/assets ratio than last year.
4AB.DE Yearly Shares Outstanding4AB.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B
4AB.DE Yearly Total Debt VS Total Assets4AB.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • 4AB has an Altman-Z score of 2.44. This is not the best score and indicates that 4AB is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of 4AB (2.44) is better than 65.06% of its industry peers.
  • The Debt to FCF ratio of 4AB is 3.79, which is a good value as it means it would take 4AB, 3.79 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.79, 4AB belongs to the top of the industry, outperforming 81.93% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.79
Altman-Z 2.44
ROIC/WACC1.76
WACC8.2%
4AB.DE Yearly LT Debt VS Equity VS FCF4AB.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20B 40B 60B

2.3 Liquidity

  • 4AB has a Current Ratio of 0.67. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 4AB has a Current ratio of 0.67. This is in the lower half of the industry: 4AB underperforms 78.31% of its industry peers.
  • 4AB has a Quick Ratio of 0.67. This is a bad value and indicates that 4AB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • 4AB has a worse Quick ratio (0.56) than 79.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.67
Quick Ratio 0.56
4AB.DE Yearly Current Assets VS Current Liabilites4AB.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

4

3. 4AB.DE Growth Analysis

3.1 Past

  • 4AB shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.19%.
  • Measured over the past years, 4AB shows a decrease in Earnings Per Share. The EPS has been decreasing by -0.99% on average per year.
  • 4AB shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 8.57%.
  • Measured over the past years, 4AB shows a small growth in Revenue. The Revenue has been growing by 5.95% on average per year.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)8.57%
Revenue growth 3Y1.75%
Revenue growth 5Y5.95%
Sales Q2Q%10.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 15.08% on average over the next years. This is quite good.
  • 4AB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.43% yearly.
EPS Next Y48.4%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
EPS Next 5Y15.08%
Revenue Next Year10.06%
Revenue Next 2Y9.15%
Revenue Next 3Y8.57%
Revenue Next 5Y6.43%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4AB.DE Yearly Revenue VS Estimates4AB.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
4AB.DE Yearly EPS VS Estimates4AB.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

7

4. 4AB.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 22.69, 4AB is valued on the expensive side.
  • Based on the Price/Earnings ratio, 4AB is valued a bit cheaper than the industry average as 79.52% of the companies are valued more expensively.
  • 4AB's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.15.
  • 4AB is valuated correctly with a Price/Forward Earnings ratio of 15.28.
  • 95.18% of the companies in the same industry are more expensive than 4AB, based on the Price/Forward Earnings ratio.
  • The average S&P500 Price/Forward Earnings ratio is at 24.27. 4AB is valued slightly cheaper when compared to this.
Industry RankSector Rank
PE 22.69
Fwd PE 15.28
4AB.DE Price Earnings VS Forward Price Earnings4AB.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 4AB's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. 4AB is cheaper than 79.52% of the companies in the same industry.
  • Based on the Price/Free Cash Flow ratio, 4AB is valued cheaper than 84.34% of the companies in the same industry.
Industry RankSector Rank
P/FCF 22.5
EV/EBITDA 15.87
4AB.DE Per share data4AB.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of 4AB may justify a higher PE ratio.
  • 4AB's earnings are expected to grow with 22.01% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y28.14%
EPS Next 3Y22.01%

6

5. 4AB.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.98%, 4AB has a reasonable but not impressive dividend return.
  • Compared to an average industry Dividend Yield of 0.66, 4AB pays a better dividend. On top of this 4AB pays more dividend than 96.39% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, 4AB pays a better dividend.
Industry RankSector Rank
Dividend Yield 2.98%

5.2 History

  • On average, the dividend of 4AB grows each year by 6.76%, which is quite nice.
Dividend Growth(5Y)6.76%
Div Incr Years4
Div Non Decr Years4
4AB.DE Yearly Dividends per share4AB.DE Yearly Dividends per shareYearly Dividends per share 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 278.48% of the earnings are spent on dividend by 4AB. This is not a sustainable payout ratio.
  • 4AB's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP278.48%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
4AB.DE Yearly Income VS Free CF VS Dividend4AB.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B
4AB.DE Dividend Payout.4AB.DE Dividend Payout, showing the Payout Ratio.4AB.DE Dividend Payout.PayoutRetained Earnings

4AB.DE Fundamentals: All Metrics, Ratios and Statistics

ABBVIE INC

FRA:4AB (3/12/2026, 5:14:15 PM)

195.8

-0.4 (-0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners76.17%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap346.21B
Revenue(TTM)61.16B
Net Income(TTM)4.19B
Analysts77.44
Price Target216.59 (10.62%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.98%
Yearly Dividend5.71
Dividend Growth(5Y)6.76%
DP278.48%
Div Incr Years4
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.46%
Min EPS beat(2)0.18%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.25%
Min EPS beat(4)0.18%
Max EPS beat(4)2.75%
EPS beat(8)8
Avg EPS beat(8)1.12%
EPS beat(12)10
Avg EPS beat(12)0.74%
EPS beat(16)12
Avg EPS beat(16)0.58%
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)-0.78%
Revenue beat(4)2
Avg Revenue beat(4)0.07%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.21%
Revenue beat(12)5
Avg Revenue beat(12)0.03%
Revenue beat(16)5
Avg Revenue beat(16)-0.64%
PT rev (1m)1.22%
PT rev (3m)1.57%
EPS NQ rev (1m)-3.54%
EPS NQ rev (3m)-1.59%
EPS NY rev (1m)2.19%
EPS NY rev (3m)2.16%
Revenue NQ rev (1m)-1.76%
Revenue NQ rev (3m)-1.04%
Revenue NY rev (1m)0.2%
Revenue NY rev (3m)0.6%
Valuation
Industry RankSector Rank
PE 22.69
Fwd PE 15.28
P/S 6.56
P/FCF 22.5
P/OCF 21.07
P/B N/A
P/tB N/A
EV/EBITDA 15.87
EPS(TTM)8.63
EY4.41%
EPS(NY)12.81
Fwd EY6.54%
FCF(TTM)8.7
FCFY4.44%
OCF(TTM)9.29
OCFY4.75%
SpS29.87
BVpS-1.6
TBVpS-44.71
PEG (NY)0.47
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 3.12%
ROE N/A
ROCE 23.09%
ROIC 14.42%
ROICexc 15.28%
ROICexgc N/A
OM 34.23%
PM (TTM) 6.84%
GM 71.62%
FCFM 29.13%
ROA(3y)3.28%
ROA(5y)5.23%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)12.12%
ROIC(5y)11.88%
ROICexc(3y)13.19%
ROICexc(5y)12.96%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.1%
ROCE(5y)18.64%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y5.79%
ROICexc growth 5Y14.56%
OM growth 3Y-0.41%
OM growth 5Y2.75%
PM growth 3Y-30.39%
PM growth 5Y-7.2%
GM growth 3Y0.04%
GM growth 5Y1.44%
F-Score8
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.79
Debt/EBITDA 2.11
Cap/Depr 14.92%
Cap/Sales 1.98%
Interest Coverage 6.97
Cash Conversion 65.45%
Profit Quality 425.61%
Current Ratio 0.67
Quick Ratio 0.56
Altman-Z 2.44
F-Score8
WACC8.2%
ROIC/WACC1.76
Cap/Depr(3y)11.82%
Cap/Depr(5y)10.58%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.55%
Profit Quality(3y)434.7%
Profit Quality(5y)340.33%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y48.4%
EPS Next 2Y28.14%
EPS Next 3Y22.01%
EPS Next 5Y15.08%
Revenue 1Y (TTM)8.57%
Revenue growth 3Y1.75%
Revenue growth 5Y5.95%
Sales Q2Q%10.04%
Revenue Next Year10.06%
Revenue Next 2Y9.15%
Revenue Next 3Y8.57%
Revenue Next 5Y6.43%
EBIT growth 1Y26.92%
EBIT growth 3Y1.33%
EBIT growth 5Y8.87%
EBIT Next Year42.07%
EBIT Next 3Y19.5%
EBIT Next 5Y10.21%
FCF growth 1Y-0.09%
FCF growth 3Y-9.76%
FCF growth 5Y1.19%
OCF growth 1Y1.19%
OCF growth 3Y-8.62%
OCF growth 5Y1.59%

ABBVIE INC / 4AB.DE FAQ

What is the ChartMill fundamental rating of ABBVIE INC (4AB.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to 4AB.DE.


What is the valuation status for 4AB stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (4AB.DE). This can be considered as Undervalued.


How profitable is ABBVIE INC (4AB.DE) stock?

ABBVIE INC (4AB.DE) has a profitability rating of 7 / 10.


Can you provide the financial health for 4AB stock?

The financial health rating of ABBVIE INC (4AB.DE) is 3 / 10.


How sustainable is the dividend of ABBVIE INC (4AB.DE) stock?

The dividend rating of ABBVIE INC (4AB.DE) is 6 / 10 and the dividend payout ratio is 278.48%.